Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy
-
- OHISHI Waka
- Department of Clinical Studies, Radiation Effects Research Foundation
-
- CHAYAMA Kazuaki
- Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University
Search this Article
Author(s)
-
- OHISHI Waka
- Department of Clinical Studies, Radiation Effects Research Foundation
-
- CHAYAMA Kazuaki
- Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University
Journal
-
- Clinical and experimental nephrology
-
Clinical and experimental nephrology 15(5), 634-640, 2011-10-01
References: 58
-
1
- Risk factors for hepatocellular carcinoma in a Japanese population : a nested case-control study
-
OHISHI W
Cancer Epidemiol Biomarkers Prev. 17, 846-854, 2008
Cited by (1)
-
2
- Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders
-
WANDS JR
Gastroenterology 68, 105-112, 1975
Cited by (1)
-
3
- Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study
-
LOK AS
Gastroenterology 100, 182-188, 1991
Cited by (1)
-
4
- Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease
-
SETH P
Bone Marrow Transpl. 30, 189-194, 2002
Cited by (1)
-
5
- The clinical and pathological course of hepatitis B liver disease in renal transplant recipients
-
PARFREY PS
Transplantation 37, 461-466, 1984
Cited by (1)
-
6
- The impact of renal transplantation on the course of hepatitis B liver disease
-
PARFREY PS
Transplantation 39, 610-615, 1985
Cited by (1)
-
7
- Recurrent hepatitis B in liver allograft recipients. Differentiation between viral hepatitis B and rejection
-
DEMETRIS AJ
Am J Pathol. 125, 161-172, 1986
Cited by (1)
-
8
- Liver transplantation in European patients with the hepatitis B surface antigen
-
SAMUEL D
N Engl J Med. 329, 1842-1847, 1993
Cited by (1)
-
9
- Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy
-
HUI CK
Gastroenterology 131, 59-68, 2006
Cited by (1)
-
10
- Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab
-
YEO W
J Clin Oncol. 27, 605-611, 2009
Cited by (1)
-
11
- Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection-Joint report of the Intractable Liver Disease Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral Hepatitis
-
TUBOUCHI H
Acta Hepatol Japonica 50, 38-42, 2009
Cited by (1)
-
12
- Distinct geographic distributions of hepatitis B virus genotypes in patients with acute infection in Japan
-
YOTSUYANAGI H
J Med Virol. 77, 39-46, 2005
Cited by (1)
-
13
- Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan
-
SUZUKI Y
J Med Virol. 76, 33-39, 2005
Cited by (1)
-
14
- Change of hepatitis B virus genotypes in acute and chronic infections in Japan
-
KOBAYASHI M
J Med Virol. 80, 1880-1884, 2008
Cited by (1)
-
15
- Hepatitis B virus DNA in liver, serum, and peripheral blood mononuclear cells after the clearance of serum hepatitis B virus surface antigen
-
MURAKAMI Y
J Med Virol. 72, 203-214, 2004
Cited by (1)
-
17
- Glucocorticoids in T cell development and function
-
ASHWELL JD
Annu Rev Immunol. 18, 309-345, 2000
Cited by (1)
-
18
- Hepatitis viruses under immunosuppressive agents
-
LIAW YF.
J Gastroenterol Hepatol. 13, 14-20, 1998
Cited by (1)
-
19
- Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro : CD55 and CD59 regulate complement-mediated cell lysis
-
GOLAY J
Blood 95, 3900-3908, 2000
Cited by (1)
-
20
- Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
-
SHAN D
Blood 91, 1644-1652, 1998
Cited by (1)
-
21
- Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy
-
BENZ K
Pediatr Nephrol. 19, 794-797, 2004
Cited by (1)
-
22
- Rituximab for refractory focal segmental glomerulosclerosis
-
NAKAYAMA M
Pediatr Nephrol. 23, 481-485, 2008
Cited by (1)
-
23
- Rituximab therapy for steroid-dependent minimal change nephrotic syndrome
-
GILBERT RD
Pediatr Nephrol. 21, 1698-1700, 2006
Cited by (1)
-
24
- Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult : first case report and pathophysiological considerations
-
FRANCOIS H
Am J Kidney Dis. 49, 158-161, 2007
Cited by (1)
-
25
- Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP
-
DAI MS
Ann Hematol. 83, 769-774, 2004
Cited by (1)
-
26
- Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy
-
YEO W
Hepatology 43, 209-220, 2006
Cited by (1)
-
27
- Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate
-
OSTUNI P
Ann Rheum Dis. 62, 686-687, 2003
Cited by (1)
-
28
- Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients : need for primary prophylaxis
-
ESTEVE M
Gut 53, 1363-1365, 2004
Cited by (1)
-
29
- The infectious profiles of anti-tumor necrosis factor agents in a Thai population : a retrospective study a the university-based hospital
-
SUWANNALAI P
Int J Rheum Dis. 12, 118-124, 2009
Cited by (1)
-
30
- Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection
-
MATSUMOTO T
Liver Int. 30, 1241-1242, 2010
Cited by (1)
-
31
- Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy
-
TENNEY DJ
Hepatology 49, 1503-1514, 2009
Cited by (1)
-
32
- Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection
-
AHMED A
Am J Gastroenterol. 94, 249-251, 1999
Cited by (1)
-
33
- Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy
-
YEO W
J Med Virol. 59, 263-269, 1999
Cited by (1)
-
34
- Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma
-
CLARK FL
Ann Oncol. 9, 385-387, 1998
Cited by (1)
-
35
- Entecavir as a first-line treatment for HBV reactivation following polychemotherapy for lymphoma
-
COLSON P
Br J Haematol. 143, 148-150, 2008
Cited by (1)
-
36
- Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy
-
YEO W
J Clin Oncol. 22, 927-934, 2004
Cited by (1)
-
37
- Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy
-
ROSSI G
Br J Haematol. 115, 58-62, 2001
Cited by (1)
-
38
- Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy
-
LAU GK
Gastroenterology 125, 1742-1749, 2003
Cited by (1)
-
39
- Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients : systematic review and meta-analysis
-
KATZ LH
J Viral Hepat. 15, 89-102, 2008
Cited by (1)
-
40
- Systematic review : the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy
-
LOOMBA R
Ann Intern Med. 148, 519-528, 2008
Cited by (1)
-
41
- Use of entecavir to prevent hepatitis B virus reactivation during cytotoxic chemotherapy for solid malignancy
-
OKITA R
Clin J Gastroenterol. 2, 214-217, 2009
Cited by (1)
-
42
- Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation : a review of 16 patients
-
WATANABE M
Eur J Intern Med. 21(4), 333-337, 2010
Cited by (1)
-
43
- Hepatitis B infection
-
LEE WM.
N Engl J Med. 337, 1733-1745, 1997
Cited by (26)
-
44
- Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients
-
SAMUEL D.
Lancet. 337, 813-815, 1991
DOI Cited by (8)
-
45
- Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease
-
TODO S.
Hepatology 13, 619-626, 1991
DOI Cited by (13)
-
46
- Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B
-
FONG TL.
Hepatology 18, 1313-1318, 1993
DOI Cited by (8)
-
47
- Short - Term Prednisolone for Inducing Seroconversion from Hepatitis B e Antigen to Antibody along with Chronic Active Hepatitis Type B
-
KUMADA H.
Japanese Journal of Medicine 26, 217-222, 1987
Ichushi Web Cited by (5)
-
48
- Time course of histological changes in patients with a sustained biochemical and virological response to corticosteroid withdrawal therapy for chronic hepatatis B
-
ARASE Y.
Am Coll Gastroenterol 99, 3304-3309, 1999
DOI Cited by (5)
-
49
- Hepatitis B virus DNA contains a glucocorticoid-responsive element
-
RAN TUR-KASPA
Proc Natl Acad Sci USA 83, 1627-1631, 1986
DOI Cited by (14)
-
50
- Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma
-
KUSUMOTO Shigeru , TANAKA Yasuhito , MIZOKAMI Masashi , UEDA Ryuzo
Int J Hematol 90(1), 13-23, 2009-07-15
Ichushi Web References (31) Cited by (17)
-
51
- Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy
-
KUSUMOTO Shigeru , TANAKA Yasuhito , UEDA Ryuzo , MIZOKAMI Masashi
J Gastroenterol 46(1), 9-16, 2011-01-01
Ichushi Web References (56) Cited by (3)
-
52
- Growth Inhibition of CD20-positive B Lymphoma Cell Lines by IDEC-C2B8 Anti-CD20 Monoclonal Antibody
-
TAJI Hirohumi , KAGAMI Yoshitoyo , OKADA Yasutaka , ANDOU Manabu , NISHI Yoshimi , SAITO Hidehiko , SETO Masao , MORISHIMA Yasuo
Jpn J Cancer Res 89(7), 748-756, 1998-07-31
DOI Ichushi Web References (33) Cited by (10)
-
53
- Current treatment for chronic hepatitis B in Japan
-
OHISHI W
Clin J Gastroenterol 2, 325-330, 2009
Ichushi Web Cited by (2)
-
54
- Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan
-
KUMADA Hiromitsu , OKANOUE Takeshi , ONJI Morikazu , MORIWAKI Hisataka , IZUMI Namiki , TANAKA Eiji , CHAYAMA Kazuaki , SAKISAKA Shotaro , TAKEHARA Tetsuo , OKETANI Makoto , SUZUKI Fumitaka , TOYOTA Joji , NOMURA Hideyuki , YOSHIOKA Kentaro , SEIKE Masataka , YOTSUYANAGI Hiroshi , UENO Yoshiyuki , The Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis Ministry of Health Labor and Welfare of Japan
Hepatol Res 40(1), 1-7, 2010-01-01
Ichushi Web References (11) Cited by (17)
-
55
- Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B
-
LAI CL
Clin Infect Dis 15(36), 687-696, 2003
DOI Cited by (7)
-
56
- Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation
-
PICARDI M.
Bone Marrow Transplant 21, 1267-1269, 1998
DOI Cited by (4)
-
57
- Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers
-
SHIBOLET O
Blood 100, 391-396, 2002
DOI Cited by (4)
-
58
- Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan
-
Umemura T , Tanaka E , Kiyosawa K , Kumada H
CLINICAL INFECTIOUS DISEASES 47(5), E52-E56, 2008-09
IR Cited by (30)